18th February 2011
What we have in place in Europe already provides an excellent means for bringing products to market. Many would consider the Centralised Procedure, which was first introduced in 1995, the ideal route for approval within Europe. Since 2005 the Centralise...
Read >
18th February 2011
The issue of access to medicines is very important to patients and even more so when considering access to orphan drugs. The EMA is currently working on the idea of creating a working party that would bring together the information that is required by all...
Read >
18th February 2011
Patients are already involved in regulatory procedures at the European Medicines Agency (EMA) with patient representation on three of the scientific committees but in the decision of public access could patients be more involved in the Health Technology A...
Read >
RSS Feed